journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/28649984/cd27-expression-and-its-association-with-clinical-outcome-in-children-and-adults-with-pro-b-acute-lymphoblastic-leukemia
#1
D Chen, N Gerasimčik, A Camponeschi, Y Tan, Q Wu, S Brynjolfsson, J Zheng, J Abrahamsson, J Nordlund, G Lönnerholm, L Fogelstrand, I-L Mårtensson
No abstract text is available yet for this article.
June 23, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28649983/high-rate-of-event-free-survival-at-24-months-with-everolimus-rchop-for-untreated-diffuse-large-b-cell-lymphoma-updated-results-from-ncctg-n1085-alliance
#2
T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell, P B Johnston
No abstract text is available yet for this article.
June 23, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622306/changes-in-uninvolved-immunoglobulins-during-induction-therapy-for-newly-diagnosed-multiple-myeloma
#3
P Ravi, S Kumar, W Gonsalves, F Buadi, M Q Lacy, R S Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel, S V Rajkumar
Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone (RD), bortezomib and dexamethasone (VD), bortezomib, cyclophosphamide and dexamethasone (VCD) or bortezomib, lenalidomide and dexamethasone (VRD) for newly diagnosed MM at our institution between 2000 and 2013, and who had available data on absolute lymphocyte count (ALC) and quantitative uninvolved Ig at baseline and at the end of four cycles of therapy...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622305/the-thrombopoietin-mpl-axis-is-activated-in-the-gata1-low-mouse-model-of-myelofibrosis-and-is-associated-with-a-defective-rps14-signature
#4
M Zingariello, L Sancillo, F Martelli, F Ciaffoni, M Marra, L Varricchio, R A Rana, C Zhao, J D Crispino, A R Migliaccio
Myelofibrosis (MF) is characterized by hyperactivation of thrombopoietin (TPO) signaling, which induces a RPS14 deficiency that de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. As mice carrying the hypomorphic Gata1(low) mutation, which reduces the levels of Gata1 mRNA in megakaryocytes, develop MF, we investigated whether the TPO axis is hyperactive in this model. Gata1(low) mice contained two times more Tpo mRNA in liver and TPO in plasma than wild-type littermates. Furthermore, Gata1(low) LSKs expressed levels of Mpl mRNA (five times greater than normal) and protein (two times lower than normal) similar to those expressed by LSKs from TPO-treated wild-type mice...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622304/outcomes-of-newly-diagnosed-myeloma-patients-requiring-dialysis-renal-recovery-importance-of-rapid-response-and-survival-benefit
#5
M A Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, D C Ziogas, M Migkou, I Panagiotidis, E Eleutherakis-Papaiakovou, N Kanellias, E Psimenou, S Marinaki, D Bacharaki, D Mparmparoussi, C Matsouka, S Giannouli, E Terpos, E Kastritis
No abstract text is available yet for this article.
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622303/addition-of-cyclophosphamide-and-higher-doses-of-dexamethasone-do-not-improve-outcomes-of-patients-with-al-amyloidosis-treated-with-bortezomib
#6
E Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, D C Ziogas, M Migkou, E Eleutherakis-Papaiakovou, I Panagiotidis, N Kanellias, E Psimenou, E Papadopoulou, C Pamboucas, E Manios, H Gakiopoulou, A Ntalianis, A Tasidou, S Giannouli, E Terpos, M A Dimopoulos
Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves efficacy, given the substantial activity of bortezomib itself. We retrospectively compared the outcomes of 101 patients with AL amyloidosis who received VD (n=59) or VCD (n=42) in two consecutive periods...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622302/evaluation-of-coagulopathy-before-and-during-induction-chemotherapy-for-acute-lymphoblastic-leukaemia-including-assessment-of-global-clotting-tests
#7
K Burley, J Salem, T Phillips, C Reilly-Stitt, D I Marks, O Tunstall, J Moppett, A Mumford, C A Bradbury
No abstract text is available yet for this article.
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622301/assessing-the-effect-of-obesity-related-traits-on-multiple-myeloma-using-a-mendelian-randomisation-approach
#8
M Went, A Sud, P J Law, D C Johnson, N Weinhold, A Försti, M van Duin, J S Mitchell, B Chen, R Kuiper, O W Stephens, U Bertsch, C Campo, H Einsele, W M Gregory, M Henrion, J Hillengass, P Hoffmann, G H Jackson, O Lenive, J Nickel, M M Nöthen, M I da Silva Filho, H Thomsen, B A Walker, A Broyl, F E Davies, C Langer, M Hansson, M Kaiser, P Sonneveld, H Goldschmidt, K Hemminki, B Nilsson, G J Morgan, R S Houlston
No abstract text is available yet for this article.
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28574489/systematic-comparison-of-donor-chimerism-in-peripheral-blood-and-bone-marrow-after-hematopoietic-stem-cell-transplantation
#9
C Bach, M Steffen, W Roesler, J Winkler, A Mackensen, K-D Stachel, M Metzler, B M Spriewald
No abstract text is available yet for this article.
June 2, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28574488/maintenance-therapy-with-alternating-azacitidine-and-lenalidomide-in-elderly-fit-patients-with-poor-prognosis-acute-myeloid-leukemia-a-phase-ii-multicentre-filo-trial
#10
M Hunault-Berger, N Maillard, C Himberlin, C Recher, A Schmidt-Tanguy, B Choufi, C Bonmati, M Carré, M-A Couturier, E Daguindau, J-P Marolleau, F Orsini-Piocelle, J Delaunay, E Tavernier, S Lissandre, M Ojeda-Uribe, L Sanhes, L Sutton, A Banos, L M Fornecker, M Bernard, D Bouscary, A Saad, M Puyade, V Rouillé, I Luquet, M C Béné, J-F Hamel, F Dreyfus, N Ifrah, A Pigneux
No abstract text is available yet for this article.
June 2, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28574487/cd123-target-validation-and-preclinical-evaluation-of-adcc-activity-of-anti-cd123-antibody-csl362-in-combination-with-nks-from-aml-patients-in-remission
#11
L H Xie, M Biondo, S J Busfield, A Arruda, X Yang, G Vairo, M D Minden
Despite the heterogeneity of acute myeloid leukemia (AML), overexpression of the interleukin-3 receptor-α (CD123) on both the more differentiated leukemic blast and leukemic stem cells (LSCs) provides a therapeutic target for antibody treatment. Here we present data on the potential clinical activity of the monoclonal antibody CSL362, which binds to CD123 with high affinity. We first validated the expression of CD123 by 100% (52/52) of patient samples and the correlation of NPM1 and FLT3-ITD mutations with the high frequency of CD123 in AML...
June 2, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28548645/waldenstrom-macroglobulinemia-cells-devoid-of-btk-c481s-or-cxcr4-whim-like-mutations-acquire-resistance-to-ibrutinib-through-upregulation-of-bcl-2-and-akt-resulting-in-vulnerability-towards-venetoclax-or-mk2206-treatment
#12
A Paulus, S Akhtar, H Yousaf, A Manna, S M Paulus, Y Bashir, T R Caulfield, M Kuranz-Blake, K Chitta, X Wang, Y Asmann, R Hudec, W Springer, S Ailawadhi, A Chanan-Khan
Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. Moreover, ibrutinib-resistant disease is being steadily reported and is associated with dismal clinical outcome (overall survival of 2.9-3.1 months). To understand mechanisms of ibrutinib resistance in WM, we established ibrutinib-resistant in vitro models using validated WM cell lines. Characterization of these models revealed the absence of BTK(C481S) and CXCR4(WHIM-like) mutations...
May 26, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28548644/survival-toxicity-and-length-of-stay-after-haploidentical-or-cord-blood-transplantation-in-a-latin-american-center-a-cross-sectional-comparative-study
#13
I Esteves, F P S Santos, A A F Ribeiro, A T Kondo, J F Fernandes, F R Kerbauy, L Kerbauy, N Hamerschlak
No abstract text is available yet for this article.
May 26, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28548643/condensed-versus-standard-schedule-of-high-dose-cytarabine-consolidation-therapy-with-pegfilgrastim-growth-factor-support-in-acute-myeloid-leukemia
#14
S Jaramillo, A Benner, J Krauter, H Martin, T Kindler, M Bentz, H R Salih, G Held, C-H Köhne, K Götze, M Lübbert, A Kündgen, P Brossart, M Wattad, H Salwender, B Hertenstein, D Nachbaur, G Wulf, H-A Horst, H Kirchen, W Fiedler, A Raghavachar, G Russ, S Kremers, E Koller, V Runde, G Heil, D Weber, G Göhring, K Döhner, A Ganser, H Döhner, R F Schlenk
The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol...
May 26, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28498371/low-absolute-peripheral-blood-cd4-t-cell-count-predicts-poor-prognosis-in-r-chop-treated-patients-with-diffuse-large-b-cell-lymphoma
#15
Y Kusano, M Yokoyama, Y Terui, N Nishimura, Y Mishima, K Ueda, N Tsuyama, H Yamauchi, A Takahashi, N Inoue, K Takeuchi, K Hatake
No abstract text is available yet for this article.
May 12, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28498370/validation-of-response-assessment-according-to-international-consortium-for-mds-mpn-criteria-in-chronic-myelomonocytic-leukemia-treated-with-hypomethylating-agents
#16
M Duchmann, T Braun, J-B Micol, U Platzbecker, S Park, S Pilorge, O Beyne-Rauzy, N Vey, M Sébert, B Gruson, P-Y Dumas, R Guieze, M-L Chretien, K Laribi, Y Chait, L Legros, L Sahnes, P Hirsch, C Salanoubat, E Solary, P Fenaux, R Itzykson
No abstract text is available yet for this article.
May 12, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28452985/through-translational-prospective-study-the-gstp1-ile105val-polymorphism-emerges-as-prognostic-marker-in-de-novo-large-b-cell-lymphoma-patients
#17
M T Delamain, E C M Miranda, G J Lourenço, C A de Souza, C S P Lima
No abstract text is available yet for this article.
April 28, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28452984/frequent-somatic-mutations-in-epigenetic-regulators-in-newly-diagnosed-chronic-myeloid-leukemia
#18
E Togasaki, J Takeda, K Yoshida, Y Shiozawa, M Takeuchi, M Oshima, A Saraya, A Iwama, K Yokote, E Sakaida, C Hirase, A Takeshita, K Imai, H Okumura, Y Morishita, N Usui, N Takahashi, S Fujisawa, Y Shiraishi, K Chiba, H Tanaka, H Kiyoi, K Ohnishi, S Ohtake, N Asou, Y Kobayashi, Y Miyazaki, S Miyano, S Ogawa, I Matsumura, C Nakaseko, T Naoe
Although tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML), the ability of TKIs to eradicate CML remains uncertain and patients must continue TKI therapy for indefinite periods. In this study, we performed whole-exome sequencing to identify somatic mutations in 24 patients with newly diagnosed chronic phase CML who were registered in the JALSG CML212 study. We identified 191 somatic mutations other than the BCR-ABL1 fusion gene (median 8, range 1-17)...
April 28, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430176/low-absolute-peripheral-blood-cd4-t-cell-count-predicts-poor-prognosis-in-r-chop-treated-patients-with-diffuse-large-b-cell-lymphoma
#19
Y Kusano, M Yokoyama, Y Terui, N Nishimura, Y Mishima, K Ueda, N Tsuyama, Y Hirofumi, A Takahashi, N Inoue, K Takeuchi, K Hatake
The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but it remains unclear as to which peripheral blood lymphocyte population is reflective of DLBCL prognosis. In this cohort, 355 patients with DLBCL treated with R-CHOP from 2006 to 2013 were analyzed. The low absolute CD4+ T-cell count (ACD4C) at diagnosis negatively correlated with the overall response rate and the complete response rate significantly (P<0...
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430175/carfilzomib-lenalidomide-dexamethasone-vs-lenalidomide-dexamethasone-in-relapsed-multiple-myeloma-by-previous-treatment
#20
M A Dimopoulos, A K Stewart, T Masszi, I Špička, A Oriol, R Hájek, L Rosiñol, D Siegel, G G Mihaylov, V Goranova-Marinova, P Rajnics, A Suvorov, R Niesvizky, A Jakubowiak, J San-Miguel, H Ludwig, S Ro, S Aggarwal, P Moreau, A Palumbo
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR)=0.690; P=0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide...
April 21, 2017: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"